Tipifarnib in Treating Patients With Advanced Hematologic Cancer
- Conditions
- LymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesLeukemiaChronic Myeloproliferative Disorders
- Interventions
- Registration Number
- NCT00005967
- Lead Sponsor
- National Cancer Institute (NCI)
- Brief Summary
Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Detailed Description
OBJECTIVES:
I. Determine the relationship between tipifarnib dose and inhibition of farnesylation in malignant cells of patients with advanced hematologic malignancies.
II. Determine the safety profile of this drug in this patient population. III. Determine the clinical activity of this drug in these patients.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 4 dose levels.
Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 36
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Arm I tipifarnib Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Chicago Cancer Research Center
🇺🇸Chicago, Illinois, United States